Myopia
Conditions
Interventions
650nm Diffuse RLRL group:650nm Diffuse RLRL
650nm RLRL group:650nm laser RLRL
650nm LED RLRL group:650nm LED RLRL group
Sponsors
Tianjin Medical University Eye Hospital
Eligibility
Sex/Gender
All
Age
8 Years to 13 Years
Inclusion criteria
Inclusion criteria: 1: 8–13 year old , regardless of gender 2: Spherical Equivalent Refraction (SER) -4.00 D to -0.50 D 3: Astigmatism <2.50 D 4: Anisometropia<1.50 D 5: No other organic ocular diseases affecting vision in both eyes 6: The subject and their guardian are able to understand the purpose of this trial, sign the informed consent form, and the subject can cooperate with the treatment and related ophthalmic examinations. No other myopia control measures apart from the study protocol will be adopted during the entire research period
Exclusion criteria
Exclusion criteria: 1: Previous myopia control treatments such as anticholinergic drugs (e.g., atropine) within the past 3 months, or participation in other functional spectacle lenses, functional soft contact lenses, etc. 2: Diagnosed color vision abnormalities 3: History of photosensitivity, glaucoma, glaucomatocyclitic crisis, ocular hypertension, macular lesions, or retinal damag 4: Systemic diseases involving the heart, liver, kidneys, etc., or congenital hereditary myopia 5: Ocular trauma, manifest strabismus, history of eye surgery, chronic eye conditions such as allergic conjunctivitis, etc 6: Pre-existing conditions such as entropion or trichiasis, severe corneal or conjunctival infections, or other ocular diseases 7: Neurological disorders, allergies or contraindications to atropine or other therapeutic drugs 8: Patients with systemic or autoimmune diseases such as albinism, psoriasis, nephrotic syndrome, systemic lupus erythematosus, diabetes, etc. 9: Any other conditions deemed by the researcher as unsuitable for participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of axial length; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in Spherical Equivalent;Changes in Choroidal Thickness;Changes of axial length, Spherical Equivalent, Choroidal Thicknessafter withdrawal; | — |
Countries
China
Contacts
Public ContactYang Jing
Tianjin Medical University Eye Hospital
Outcome results
None listed